Patent Awarded to eGene
News Oct 31, 2005
eGene has announced that the US Patent Office has issued a patent (US 6929779) to the company entitled “Optical detection in bio-separation device using axial radiation output.”
According to eGene’s CEO, Dr. Ming S. Liu, “eGene has revolutionized the bioanalysis market by developing a highly affordable, high performance bio-separation instrument that integrates our novel detection technology.”
eGene was also granted a similar patent from the US Patent Office entitled “Optical detection in bio-separation device using a widened detection zone” (US 6529275) in May 2003.
In mid-2004, eGene launched its high performance genetic analyzer (HDA-GT12™) using its cutting-edge multiple channel capillary electrophoresis technology. The company has shipped over 100 units to research laboratories worldwide.
These instruments are being currently used for wide variety of applications including microsatellites, restriction digest DNA, AFLP, RFLP, RNA sample quality check and oligonucleotide quality check.
“Eventually, researchers will be able to use the power of capillary electrophoresis systems for their targeted applications, so any lab can purchase our affordable instrument, put it on the bench top, and perform procedures that take 5 to 10 minutes,” said Monisha Singh, eGene’s Global Marketing Manager.
Unlike most cells in the rest of our body, the DNA (the genome) in each of our brain cells varies from cell to cell, caused by somatic changes. But much remains unknown, including when these changes arise, their size and locations, and whether they are random or regulated. Now, researchers have developed new techniques allowing the detection of CNVs smaller than one million base pairs.